Irinotecan Hydrochloride Eugia (Uk) (Irinotecan Hydrochloride Trihydrate)

The drug is a pro‑drug that is converted inside cancer cells to SN‑38, which inhibits topoisomerase I. This enzyme normally relieves DNA supercoiling during replication; its inhibition leads to accumulation of DNA breaks, triggering cell death in rapidly dividing tumor cells.

The dosing regimen for Irinotecan Hydrochloride is determined by the prescribing oncologist based on the patient’s weight, disease stage, and treatment protocol. Specific dose calculations and schedules are individualized and should follow established clinical guidelines.

Safety data for Irinotecan Hydrochloride in pregnancy and lactation are limited. It is generally contraindicated in pregnant or nursing women because of potential fetal toxicity and drug excretion in breast milk. Consultation with a specialist is essential before use.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a distinct mechanism from fluoropyrimidines or oxaliplatin. It is often combined with these agents to enhance efficacy. Compared with alternatives, Irinotecan provides a different toxicity profile, notably higher rates of diarrhea and neutropenia, which may influence regimen selection.

The injectable formulation should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. Prior to administration, the solution must be inspected for particulate matter and used within the time frame specified by the manufacturer’s labeling.

Irinotecan Hydrochloride is given by intravenous infusion, typically over 30‑90 minutes depending on the protocol. Administration is performed in a clinical setting by qualified healthcare professionals, with monitoring for infusion‑related reactions and supportive care as needed.

The most serious adverse events include severe neutropenia leading to infection, febrile neutropenia, life‑threatening diarrhea, intestinal perforation, and hepatic toxicity. Prompt recognition and management of these conditions are critical to patient safety.

Patients with known hypersensitivity to Irinotecan or its excipients, those with severe hepatic impairment, and individuals with active uncontrolled infections should avoid the drug. Additionally, patients with a history of severe bowel disease may be at increased risk for complications.